Approved Hospital Formulary
Add Formweb to your mobile device
Search results for:
ranibizumab ophthalmic
ranibizumab ophthalmic
Brand names: Lucentis, Susvimo Implant Kit
| Form | Strength |
|---|---|
| SOLUTION, INTRAVITREAL | 6 mg/mL, 10 mg/mL; 100 mg/mL |
Last updated: Jun. 10, 2022
- Black Box Warning: Endophthalmitis
- Restricted Susvimo: Formulary Restricted Medication
Ranibizumab implant (Susvimo): Formulary, Restricted to use by Devers, for adults patients with neovascular age related macular degeneration (nAMD) who have failed (or are not appropriate for) bevacizumab (Avastin) and have exhibited tolerance of and clinical response to ranibizumab injection (Lucentis).